1. Search Result
Search Result
Results for "

fibrosis-related diseases

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

2

Inhibitory Antibodies

4

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-128483

    TGF-beta/Smad PI3K NF-κB Akt Apoptosis Dopamine β-hydroxylase mTOR Adrenergic Receptor Cardiovascular Disease Endocrinology Cancer
    Fusaric acid is an orally active multi-pathway inhibitor with the activity of inducing oxidative stress and apoptosis. Fusaric acid can chelate divalent metal cations, damage mitochondrial membrane structure, and activate apoptosis-related proteases such as Caspase-3/7, -8, and -9. Fusaric acid also regulates Bax/Bcl-2 protein, inhibits fibrosis-related signaling pathways such as NF-κB, TGF-β1/SMADs, and PI3K/AKT/mTOR, and reduces collagen deposition. Fusaric acid is also a dopamine β-hydroxylase inhibitor, which reduces endogenous levels of norepinephrine and epinephrine in the brain, heart, spleen, and adrenal glands. Fusaric acid can play a role in myocardial fibrosis and improve cardiac hypertrophy in heart disease, and can also be used in the study of esophageal cancer and liver cancer .
    Fusaric acid
  • HY-P991363

    Myosin STAT Inflammation/Immunology
    AX-202 is a humanized IgG4 monoclonal antibody targeting S100A4. AX-202 neutralizes the activity of S100A4. AX-202 effectively reverses established fibrosis and reduces inflammation and fibrosis-related biomarkers in a mouse model of skin fibrosis. AX-202 is applicable for the research of fibrotic and inflammatory diseases .
    AX-202
  • HY-128437
    TGFβ-IN-5
    1 Publications Verification

    TGF-β Receptor Inflammation/Immunology
    TGFβ-IN-5 is a type I transforming growth factor-β receptor (TGF-β R1) kinase inhibitor with an IC50 value of 0.0485 μM. TGFβ-IN-5 reverses the effect of TGF-β-mediated cell activation on the expression of fibrosis-related genes. TGFβ-IN-5 can be used in the research of fibroproliferative diseases .
    TGFβ-IN-5
  • HY-N10423

    (-)-Cubebin

    Cholinesterase (ChE) Bacterial Fungal Parasite p38 MAPK Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Cubebin ((-)-Cubebin), a dibenzyl butyrolactone lignan, is an orally active AChE inhibitor. Cubebin binds to active sites of NF-κB, TNF-α, and TGF-β1 via hydrogen and hydrophobic interactions, obstructing critical residues to inhibit pro-inflammatory or renal fibrosis-related activity. Cubebin enhances p38 MAPK phosphorylation to increase tyrosinase gene expression, stimulating melanogenesis via elevated tyrosinase activity, expression, and mRNA levels. Cubebin reduces oxidative stress via enhanced endogenous antioxidant enzyme activity and inhibited lipid peroxidation, regulates lipid metabolism, improves glycemic control, and exerts renoprotective effects via reduced renal dysfunction markers and improved renal architecture. Cubebin shows antimicrobial activity. Cubebin exerts larvicidal activity against Angiostrongylus cantonensis larvae, with no cytotoxicity toward monkey or human cell lines or Caenorhabditis elegans. Cubebin can be used for the research of diabetic nephropathy, melanoma, colon adenocarcinoma, neuroangiostrongyliasis, Alzheimer’s disease (AD) and depression .
    Cubebin
  • HY-169940

    HDAC Inflammation/Immunology
    Fibrostat (Compound 5n) is a selective HDAC6 inhibitor that exerts antifibrotic effects by inhibiting HDAC6 activity, with an IC50 value of 63 nM. It also exhibits good selectivity over HDAC1, HDAC3, HDAC5, HDAC8, HDAC10, and HDAC11. Fibrostat significantly downregulates fibrotic markers (fibronectin and collagen 1) in fibroblasts. Additionally, Fibrostat demonstrated no toxicity in rat-perfused heart and zebrafish larvae models. Fibrostat shows potential for research into fibrosis-related diseases .
    Fibrostat
  • HY-172258

    5-HT Receptor Cancer
    5-HT2B antagonist-2 (Compound 19c) is a 5HT2B receptor antagonist with an IC50 of 1.09 nM. 5-HT2B antagonist-2 can downregulate the expression of fibrosis-related genes α-SMA, Timp1, Col1a1, and Col3a1, and significantly reduce the deposition of fibrosis, thereby reducing the fibrotic area and inhibiting the fibrotic process in CCl4-induced liver fibrosis mouse models. 5-HT2B antagonist-2 can be used in the study of immune inflammatory-related diseases, particularly in the research of pulmonary fibrosis diseases .
    5-HT2B antagonist-2
  • HY-128483R

    TGF-beta/Smad PI3K NF-κB Akt Apoptosis Dopamine β-hydroxylase mTOR Adrenergic Receptor Reference Standards Cardiovascular Disease Endocrinology Cancer
    Fusaric acid (Standard) is the analytical standard of Fusaric acid (HY-128483). This product is intended for research and analytical applications. Fusaric acid is an orally active multi-pathway inhibitor with the activity of inducing oxidative stress and apoptosis. Fusaric acid can chelate divalent metal cations, damage mitochondrial membrane structure, and activate apoptosis-related proteases such as Caspase-3/7, -8, and -9. Fusaric acid also regulates Bax/Bcl-2 protein, inhibits fibrosis-related signaling pathways such as NF-κB, TGF-β1/SMADs, and PI3K/AKT/mTOR, and reduces collagen deposition. Fusaric acid is also a dopamine β-hydroxylase inhibitor, which reduces endogenous levels of norepinephrine and epinephrine in the brain, heart, spleen, and adrenal glands. Fusaric acid can play a role in myocardial fibrosis and improve cardiac hypertrophy in heart disease, and can also be used in the study of esophageal cancer and liver cancer .
    Fusaric acid (Standard)
  • HY-P992313

    PAI-1 Cardiovascular Disease
    AS3288802, a highly selective active plasminogen activator inhibitor-1 (PAI-1) antibody, is a PAI-1 inhibitor with a human IC50 and EC50 values of 4.2 ng/mL. AS3288802 can be used for the research of thrombosis and fibrosis-related diseases .
    AS3288802
  • HY-183651

    15-PGDH Inflammation/Immunology
    15-PGDH-IN-5 (compound 5) is a sulfoxide-derived 15-PGDH inhibitor. 15-PGDH-IN-5 exhibits higher metabolic stability and superior in vivo exposure compared with the lead compound SW033291 (HY-16968). 15-PGDH-IN-5 inhibits the irreversible oxidative catabolism of PGE2 by 15-PGDH, thereby enhancing the tissue-specific bioavailability of endogenous PGE2. 15-PGDH-IN-5 exerts anti-inflammatory effects and accelerates tissue repair and regeneration, and it is used in studies on tissue injury and fibrosis-related diseases such as inflammatory bowel disease and idiopathic pulmonary fibrosis .
    15-PGDH-IN-5
  • HY-N16980

    TGF-beta/Smad Inflammation/Immunology
    (7'E,8S)-2',4,8-Trihydroxy-3-methoxy-2,4'-epoxy-8,5'-neolign-7'-en-7-one (compound 4) is a novel neolignan anti-inflammatory agent. (7'E,8S)-2',4,8-Trihydroxy-3-methoxy-2,4'-epoxy-8,5'-neolign-7'-en-7-one has an IC50 of 25.2 μM against TGF-β-induced hepatic stellate cells (HSC-T6). (7'E,8S)-2',4,8-Trihydroxy-3-methoxy-2,4'-epoxy-8,5'-neolign-7'-en-7-one may be related to blocking excessive cell proliferation in the process of liver fibrosis and can be used in the study of liver fibrosis-related diseases. (7'E,8S)-2',4,8-Trihydroxy-3-methoxy-2,4'-epoxy-8,5'-neolign-7'-en-7-one can be naturally extracted from the dried aerial parts of Penthorum chinense Pursh .
    (7'E,8S)-2',4,8-Trihydroxy-3-methoxy-2,4'-epoxy-8,5'-neolign-7'-en-7-one

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: